甲状腺癌骨转移模型的研究

亓龙; 王辉

doi:10.3760/cma.j.issn.1673-4114,2010.06.003

甲状腺癌骨转移模型的研究

亓龙,
王辉

上海交通大学医学院附属新华医院核医学科, 200092

Research progress of animal model of bone metastases of thyroid carcinoma

QI Long,
WANG Hui

Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University of Medicine, Shanghai 200092, China

摘要: 甲状腺癌是内分泌系统最常见的恶性肿瘤,其发病率逐年上升,虽然该病预后较好,但若发生骨转移,患者10年生存率将明显降低。目前,甲状腺癌发生骨转移的机制尚不明确,对甲状腺癌骨转移的研究不仅具有重要的临床价值,也有很重要的科研价值。甲状腺癌骨转移动物模型的建立是研究甲状腺癌骨转移机制和治疗的基础,根据其建立方法可分为自发性、化学诱导性、转基因诱导性和移植性4种。
- 甲状腺肿瘤 /
- 肿瘤转移 /
- 模型,动物
Abstract: Thyroid carcinoma is the most common endocrine malignancy, its incidence rate increases year by year. Although the disease has good prognosis, if bone metastases happen, 10-year survival rate of patients will obviously reduce. At present, the mechanism of the occurrence of bone metastases is not clear.The research of bone metastases of thyroid carcinoma not only has important clinical value, but also scientific value. Animal model of bone metastasis of thyroid carcinoma is the basis to study the mechanism and therapy of thyroid carcinoma. According to its establishment methods, it can be divided into four types, including spontaneous type, chemical induced type, transgenic induced type and transplanted type.
- Thyroid neoplasms /
- Neoplasm metastasis /
- Models,animal
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma:a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol, 2009, 20(10):1728-1735.
[2]	Muresan MM, Olivier P, Leclere J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer, 2008, 15(1):37-49.
[3]	Mihailovic JM, Stefanovic LJ, Malesevic MD, et al. Metastatic differentiated thyroid carcinoma:clinical management and outcome of disease in patients with initial and late distant metastases. Nucl Med Commun, 2009, 30(7):558-564.
[4]	Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006, 91(8):2892-2899.
[5]	Schlumberger M, Tubiana M. De Vathaire F, et al. Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab, 1986, 63(4):960-967.
[6]	Sugltani I, Fujimoto Y, Yamamoto N, et al. Papillary thyroid carcinoma with distant metastases:survival predictors and the importance of local control. Surgery, 2008, 143(1):35-42.
[7]	Baitei EY, Zou M, A1-Mohanna F, et al. Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol, 2009, 217(5):707-715.
[8]	Kogai T, Sajid-Crockett S, Newmarch LS, et al. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid ceils and human papillary thyroid cancer cells. J Endocrinol, 2008, 199(2):243-252.
[9]	Ahn SH, Henderson Y, Kang Y, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg, 2008, 134(2):190-197.
[10]	Younes MN, Kim S, Yigitbasi OG, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 2005, 4(8):1146-1156.
[11]	Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid, 2009, 19(8):825-835.
[12]	Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep, 2010, 23(6):1721-1727.
[13]	Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endoerinol Metab, 2008, 93(11):4331-4341.
[14]	Klopper JP, Berenz A, Hays WR, et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res, 2008, 14(2):589-596.
[15]	Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther, 2007, 6(6):1785-1792.
[16]	Nahari D, Satchi-Fainaro RS, Chen M, et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther, 2007, 6(4):1329-1337.
[17]	Lin X, Zhu B, Liu Y, et al. Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagn Pathol, 2010, 5:8.
[18]	Hombaeh-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[19]	Ereolino T, Lombardi A, Becherini L, et al. The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol (Oxt), 2008, 69(2):253-258.
[20]	Quidville V, Segond N, Tebbi A, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid, 2009, 19(6):613-621.
[21]	Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer, 2010, 18(1):1-11.
[22]	Chen MC, Yu CH, Wang SW, et al. Anti-proliferative effects of evodiamine on human thyroid eancer cell line ARO. J Cell Biochem, 2010, 110(6):1495-1503.
[23]	Arcinas A, Yen TY, Kebebew E, et al. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res, 2009, 8(8):3958-3968.
[24]	Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol, 2007, 264(1-2):74-81.
[25]	Fortin MA, Salnikov AV, Nestor M, et al. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36:application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging, 2007, 34(9):1376-1387.
[26]	Leux C, Guénel P. Risk factors of thyroid tumors:role of environmental and occupational exposures to chemical pollutants. Rev Epidemiol Sante Publique, 2010, 58(5):359-367.
[27]	Alfano RW, Leppla SH, Liu S, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther, 2010, 9(1):190-201.
[28]	Hombach-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[29]	Zatelli MC, Tagliati F, Amodio V, et al. Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma. Anal Cell Pathol (Amst), 2010, 33(5):207-216.
[30]	Henderson YC, Ahn SH, Kang Y, et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res, 2008, 14(15):4908-4914.
[31]	Nucera C, Nehs MA, Mekel M, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid, 2009, 19(10):1077-1084.
[32]	Sehiff BA, MeMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res, 2004, 10(24):8594-8602.
[33]	Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11(5):1713-1721.
[34]	Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis:identification of S100 A4(Mtsl) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab, 2004, 89(12):6146-6154.

[1]	亓龙 , 王辉 . 甲状腺癌骨转移模型的研究. 国际放射医学核医学杂志, 2010, 34(6): 329-332. doi: 10.3760/cma.j.issn.1673-4114.2010.06.003
[2]	武晨 , 杜芬 , 刘师伟 , 马浩华 , 张海涛 , 刘静 , 张迎伟 , 罗丽萍 , 程艳 . 血清MK和Gal-3水平在甲状腺结节及DTC术后转移灶中的诊断价值. 国际放射医学核医学杂志, 2020, 44(9): 561-568. doi: 10.3760/cma.j.cn121381-201906004-00077
[3]	陈志军 , 谭丽玲 , 王文俊 , 周爱清 . ¹³¹I联合¹²⁵I粒子治疗难治性甲状腺癌骨转移一例. 国际放射医学核医学杂志, 2017, 41(1): 76-78. doi: 10.3760/cma.j.issn.1673-4114.2017.01.015
[4]	申江玉 , 晋建华 . 分化型甲状腺癌肺转移的研究进展. 国际放射医学核医学杂志, 2021, 45(10): 663-668. doi: 10.3760/cma.j.cn121381-202104027-00109
[5]	邓玮玮 , 朱娅华 , 范敏 , 张春银 . ⁹⁹Tc^mO₄^-全身显像联合颈胸SPECT/CT在DTC患者术后肺转移灶显影中的应用. 国际放射医学核医学杂志, 2018, 42(3): 207-211. doi: 10.3760/cma.j.issn.1673-4114.2018.03.003
[6]	咸雨蔚 , 左书耀 . 甲状腺肿瘤SPECT-CT融合显像的应用近况. 国际放射医学核医学杂志, 2006, 30(3): 157-160.
[7]	易艳玲 , 卓维海 . ¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析. 国际放射医学核医学杂志, 2008, 32(6): 372-375.
[8]	张胤 , 陈跃 . ¹⁸F-氟化钠PET/CT诊断肿瘤骨转移应用进展. 国际放射医学核医学杂志, 2015, 39(1): 96-102. doi: 10.3760/cma.j.issn.1673-4114.2015.01.020
[9]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[10]	潘懿范 , 宋少莉 , 黄钢 . 比较SPECT-CT和PET-CT在小动物模型中的应用. 国际放射医学核医学杂志, 2009, 33(4): 196-199. doi: 10.3760/cma.j.issn.1673-4114.2009.04.002

点击查看大图

计量

文章访问数: 1444
HTML全文浏览量: 241
PDF下载量: 3

甲状腺癌骨转移模型的研究

Research progress of animal model of bone metastases of thyroid carcinoma

计量

甲状腺癌骨转移模型的研究

English Abstract

Research progress of animal model of bone metastases of thyroid carcinoma

全文HTML

目录

甲状腺癌骨转移模型的研究

Research progress of animal model of bone metastases of thyroid carcinoma

计量

出版历程

甲状腺癌骨转移模型的研究

English Abstract

Research progress of animal model of bone metastases of thyroid carcinoma

全文HTML

目录